Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely prescribed to patients with osteoarthritis (OA), it was assumed that both cyclooxygenase-2 (COX-2) inhibitor and non-selective NSAIDs have similar efficacy but associated with different rates of adverse events. Imrecoxib was approved by the Chinese Food and Drug Administration (CFDA) in 2011, which is a COX-2 inhibitor. This study is aimed to access the cost-effectiveness of celecoxib, imrecoxib and diclofenac for managing OA in Chinese aged ≥55 years and ≥65 years based on the real-world data from China.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
